12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

XEN-D0103: Phase I data

A U.K. Phase I trial in 86 healthy volunteers showed that single and multiple ascending-doses of oral XEN-D0103 were well tolerated with...

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >